ULTRAGENYX PHARMACEUTICAL INC. Cost of Revenue
ULTRAGENYX PHARMACEUTICAL INC. (RARE) reported Cost of Revenue of $766.00 thousand for the 3-month period ending 2019-06-30, per its 10-Q filed 2019-08-02.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfGoodsAndServicesSold · last filed 2019-08-02
- ULTRAGENYX PHARMACEUTICAL INC. cost of goods and services sold for the quarter ending 2019-06-30 was $766.00K, a 443.26% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. cost of goods and services sold for the quarter ending 2019-03-31 was $452.00K, a 100.89% increase year-over-year.
- ULTRAGENYX PHARMACEUTICAL INC. cost of goods and services sold for the quarter ending 2018-12-31 was $507.00K.
- ULTRAGENYX PHARMACEUTICAL INC. cost of goods and services sold for the quarter ending 2018-09-30 was $273.00K.
- ULTRAGENYX PHARMACEUTICAL INC. cost of goods and services sold for fiscal 2018 was $1.15M, a 114500.00% increase from fiscal 2017.
- ULTRAGENYX PHARMACEUTICAL INC. cost of goods and services sold for fiscal 2017 was $1.00K.
| Period end | Cost of Goods and Services Sold 3 month | Cost of Goods and Services Sold 6 month | Cost of Goods and Services Sold 9 month | Cost of Goods and Services Sold 12 month |
|---|---|---|---|---|
| 2019-06-30 | $766.00K 10-Q · filed 2019-08-02 | $1.22M 10-Q · filed 2019-08-02 | $1.73M derived: sum of 3 quarters · filed 2019-08-02 | $2.00M derived: sum of 4 quarters · filed 2019-08-02 |
| 2019-03-31 | $452.00K 10-Q · filed 2019-05-07 | $959.00K derived: sum of 2 quarters · filed 2019-05-07 | $1.23M derived: sum of 3 quarters · filed 2019-05-07 | $1.37M derived: sum of 4 quarters · filed 2019-08-02 |
| 2018-12-31 | $507.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-20 | $780.00K derived: sum of 2 quarters · filed 2019-02-20 | $921.00K derived: sum of 3 quarters · filed 2019-08-02 | $1.15M 10-K · filed 2019-02-20 |
| 2018-09-30 | $273.00K 10-Q · filed 2018-11-06 | $414.00K derived: sum of 2 quarters · filed 2019-08-02 | $639.00K 10-Q · filed 2018-11-06 | |
| 2018-06-30 | $141.00K 10-Q · filed 2019-08-02 | $366.00K 10-Q · filed 2019-08-02 | ||
| 2018-03-31 | $225.00K 10-Q · filed 2019-05-07 | |||
| 2017-12-31 | $1.00K 10-K · filed 2019-02-20 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |